![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
news
Gilead opens paediatric drug development centre in Ireland
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
List view / Grid view
Hepatitis
news
3D-printed vaccine patch boasts greater immunity than usual vaccine shot
A newly designed 3D-printed microneedle patch demonstrated immune responses 50 times greater than typical subcutaneous injection in animals.
news
Global pharma contract manufacturing market to value $120bn by 2027
Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine-300x278.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine.jpg)
news
Therapeutic proteins and oral vaccines market to surpass $300,000mn by 2027
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
news
Leaked document reveals ‘unprecedented’ medicine shortages in NHS
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
news
Gilead’s Phase II study showed 99% HCV cure rates
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
news
FDA approves Roche’s blood screening assay for donor screening
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
news
AbbVie receives FDA approval for new Hepatitis C drug
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...
news
FDA approves Epclusa for treatment of chronic HCV
29 June 2016 | By Victoria White, Digital Content Producer
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
news
Positive CHMP opinion for Gilead’s Epclusa in HCV
27 May 2016 | By Victoria White, Digital Content Producer
The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus...
news
AbbVie presents data for ABT-493 and ABT-530 regimen in HCV
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
news
Gilead announces results from two Phase III studies of TAF in HBV
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
news
AbbVie presents real-world data for Viekirax + Exviera in HCV
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
news
Positive results for AbbVie’s Viekirax + Exviera regimen
14 April 2016 | By Victoria White, Digital Content Producer
AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
news
MSD announces positive results from elbasvir/grazoprevir HCV study
14 April 2016 | By Victoria White, Digital Content Producer
Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV...
